Background: Remote magnetic navigation (RMN) is often used in combination with a
| INTRODUC TI ON
Frequent premature ventricular contractions (PVCs) may be highly symptomatic leading to a significantly reduced quality-of-life, potentially contributing to congestive heart failure and increased mortality.
1,2 PVCs occur commonly in patients without structural heart disease, but can also be seen in patients with structural heart disease. 3, 4 Several studies demonstrated a significant improvement in quality-of-life and left ventricular function after successful ablation of PVCs compared to patients without ablation. 5, 6 The use of a three-dimensional (3D) mapping system is needed for a successful ablation of PVCs, with the CARTO (Biosense Webster, Inc., CA, USA) mapping system being the most used system with excellent performance. 7, 8 The downside, however, is that only the diagnostic and ablation catheters from the same manufacturer can be used with the CARTO system. The EnSite cardiac mapping system (St Jude Medical, Inc., Minnesota, USA), another 3D mapping system with an open-platform, allows for visualization of multiple catheters from different manufacturers while simultaneously collecting anatomical and electrophysiological data from all electrodes of any catheter.
9
Recent reports utilizing Ensite for PVC ablation demonstrated high success with very limited fluoroscopy. 7, 10 However, reports of dislocation of the reference catheter may lead to uncorrectable map shifts using this mapping system, which then manually needs to be adjusted. 9 The next generation of this system, EnSite Precision, was recently released, which combined both impedance and magnetic technologies with much more precision and improved stability.
11
However, the performance of this new system on ventricular arrhythmia ablation is still unknown.
Remote magnetic navigation (RMN) has emerged as a modern technology for treating most arrhythmias because of its precise control of catheter movement with improved catheter stability and safety. 12, 13 It particularly adapts to the treatment of ventricular arrhythmias and exhibits better efficacy compared to the manual technique. 14, 15 In order for the RMN system to perform ablation procedures, it needs to be integrated with a 3D mapping. 12 Currently, only CARTO mapping system is integrated with RMN, but not the EnSite system. 13 The
EnSite 3D mapping system has demonstrated safe and effective ablations of ventricular arrhythmias with low fluoroscopy exposure when performed with manual techniques. 16 Furthermore, the new features of EnSite Precision offer convenience to the operator by allowing them to map and locate the origins of even the most difficult ventricular arrhythmias. However, the collaboration of EnSite Precision with RMN on ventricular arrhythmia ablation has not been investigated.
The purpose of this study was to determine the acute procedural efficacy, safety and long-term outcome utilizing the Ensite Precision
Mapping system with RMN during PVC ablation procedures.
| ME THODS

| Study population
In this retrospective study, forty-three consecutive symptomatic patients with ectopic ventricular arrhythmias targeted for ablation were included between January 2016 and January 2018. Twentytwo patients underwent ablation using EnSite Precision mapping system (Inquiry, St Jude Medical, Inc.; Precision group) and another 21 patients used CARTO ® 3 mapping system (Biosense Webster, Inc.; CARTO group). All the patients signed informed consent prior to the ablation procedure. No patient had previously undergone an ablation and patients with polymorphic PVCs, coronary artery disease, valvular heart disease, dilated cardiomyopathy or congenital heart disease were excluded from this study. All antiarrhythmic agents were withheld for at least five drug half-lives before the procedure.
Preprocedural examination included a baseline 12-lead surface ECG and transthoracic echocardiography. In Denmark (and many other countries), a study comparing two routine methods used in the clinic, as two 3D mapping systems with identical ablation strategies in this study, does not require approval from the local ethical committee. 
| Procedural preparation
| Use of mapping systems with RMN
RMN was applied to all the procedures in this study, including first-time procedures and redo procedures. Cardiac mapping system, X-Ray, electrophysiological recording system and RMN (Stereotaxis, Inc., MO, USA)
were gathered on one monitor by Odyssey Vision™ system (Stereotaxis, Inc.). As the CARTO mapping system is integrated with the RMN system, the magnetic vector could be changed in CARTO interface to navigate the directional orientation of catheter ( Figure 1A ). While EnSite Precision mapping system was not integrated with the RMN system, the magnetic vector could only be operated in RMN system ( Figure 1B) . A catheteradvancing system (Cardiodrive ® , Stereotaxis Inc) was used to control remote catheter advancement and retraction in the control room.
| Mapping acquisition
In the Precision group, the target chamber anatomic mapping was first 
| Ablation procedure
Ablation was initiated at the earliest activation sites if the following criteria were met: local activation of clinical PVC was at least 25 ms pre-QRS, the first deflection of bipolar electrograms was negative and virtual unipolar electrograms with QS morphology. 
| Procedural characteristics measurements
The procedure time was calculated from the vein puncture to catheter withdrawal. Mapping time was calculated from the start of mapping to the start of the first RF ablation. RF ablation time and fluoroscopy time were acquired from the EP tracer and X-Ray machine records, respectively.
| Follow-up
All patients were routinely evaluated in our outpatient clinic at 3rd months after discharge, then every 6 month by their 
| Complications
Complications were divided into two categories: major and minor.
Major complications consisted of acute myocardial infarction, stroke, major bleeding, and cardiac tamponade. Minor complications included pericarditis and inguinal hematoma.
| Statistical analysis
Variables are expressed as mean ± SD. 
| RE SULTS
| Baseline characteristics of patients
Population characteristics are detailed in Table 1 
| Procedural characteristics
Procedural data are detailed in Table 2 
| Location of ablation target
The earliest activation location of PVCs was identified in all the cases and the origins of PVCs are listed in Table 3 
| Acute results and long-term follow-up
Acute results and long-term follow-up data are presented in Table 4 .
Acute ablation success was achieved in 20/22 (90.9%) patients in the Precision group and in 19/21 (90.5%) patients in the CARTO group, no statistically significance difference was found between the two groups. For the acute failed cases in the Precision group, the target in the first patient likely originated from the RVOT lateral epicardium, and was 53 ms earlier than the surface QRS, but RF ablation could not abolish the PVCs. The target in the second patient came from LV lateral wall, which might have also come from the epicardium source. Both of these patients refused the epicardial approach procedure. For the acute failed cases in the CARTO group, the target in the first patient originated from the RVOT septum with no effect by RF ablation, further investigation of the LVOT was warranted; 
TA B L E 1 Baseline characteristics of patients
however, the patient refused to continue the procedure. And this patient was re-ablated later in the LVOT septum and obtained both acute and long-term success with CARTO. In the second case, the earliest activation was found in the RVOT septum first, and an RF ablation was performed without effect. The LVOT was mapped and it was earlier than the RVOT but ablation still could not abolish the PVCs. After precise mapping, the focus was found in the main trunk of left coronary artery and ablation was not performed.
After a mean follow-up of 16.2 ± 6.2 months, the long-term success rate demonstrated no significant difference between the two groups ( Figure 3 , P = 0.650). One patient in the Precision group and two patients in the CARTO group had recurrence of PVCs with no statistical significance (P = 0.522). In the Precision group, the patient had recurrence of PVCs from the same site and a repeat ablation had both acute and long-term success. In the CARTO group, one patient with recurrence of PVCs scheduled for new ablation. Another patient with mono-morphological PVCs induced idiopathic ventricular fibrillation had a PVC recurrence, was re-ablated using EnSite Precision and achieved both acute and long-term success, and an ICD was implanted before discharge.
| D ISCUSS I ON
To the best of our knowledge, this is the first study evaluating the feasibility, safety, acute efficacy, and long-term outcome using the combination of EnSite Precision with RMN in PVC ablation. Our main finding is that even without direct integration between Precision and RMN, it was feasible to perform PVC ablation using these two systems with similar acute and long-term success as using CARTO and RMN. 
TA B L E 2 Procedural results
Location
| Generation of maps with EnSite Precision
The new-generation mapping system, EnSite Precision System uniquely combines impedance and magnetic field hybrid technology, to enable navigation and tracking of mapping or ablation catheters during the procedure. When a catheter with magnetic sensor is introduced, the system dynamically optimizes the model by adjusting the dimensions of the navigation field between the position and orientation of magnetic sensors and electrodes. The combination of impedance field and magnetic field improved the stability and accuracy of location and navigation. 11 In this study, for nine cases with PVCs from the outflow tract, the anatomical model of target cardiac chamber was performed manually with a circular mapping catheter and an anatomical model could be acquired in just a few minutes, suggesting that circular mapping catheter could be applied for outflow tract mapping.
After acquisition of the anatomical model, activation map of the PVCs was performed with the ablation catheter navigated by RMN. The acute outcome and long-term results between the circular catheter plus ablation catheter and ablation catheter only were investigated. As shown in Table S1 , there was no significant differences regarding the acute success rate (88.9% vs 92.3%, P = 0.784) and long-term success rate (88.9% vs 84.6%, P = 0.774) between the two groups.
By using the Automap module, clinical PVC was set as the template and the system correlated every beat with the template. When the score meets the criterion of the clinical PVC, the system collected the points automatically with no need of manual recognition. If the activation map was not correlated with the electrogram of local activation, a new activation map could be generated with the existing points by adjusting the collection criterion in a 10-time fast speed, which is called TurboMap (Figure 2 ). For the cases with multimorphological PVCs, TurboMap could also be applied to locate the origin of PVC one by one without manually collecting new points. Therefore, this novel mapping system facilitates catheter ablation of PVCs, especially multimorphological PVCs.
| Concurrent use of RMN and EnSite Precision
The Odyssey system combines the cardiac mapping system, X-Ray, electrophysiological recording system and RMN on one monitor, which makes it possible to operate these four systems in this unique monitor. There are three differences between CARTO and EnSite Precision when used with RMN. First, as CARTO mapping system was integrated with RMN, the vector direction of magnetic field could be changed on the 3D model in CARTO system, which made the operation of vector direction very convenient. While EnSite Precision system is not integrated with RMN, the vector direction could only be moved in the RMN system but not in the EnSite Precision system. Second, the settings for CARTO could be done in the RMN system but not within the EnSite Precision system. Third, the 3Dmodels created by CARTO could be integrated with the fluoroscopy reference, which made it feasible for the physicians to know the anatomical location of the model in the fluoroscopy reference.
However, the models obtained by EnSite Precision system could not be merged with the fluoroscopy reference.
Despite this, the mapping and ablation of PVCs using EnSite cedure duration of this current study was 96.3 ± 27.7 min, which might be shorter than previous studies using RMN but similar to manual studies. 6, 17, 18 The fluoroscopy time of the current study was 3.9 ± 1.9 min, which was shorter or similar to other studies using RMN, but was significantly lower than manual studies. [17] [18] [19] This suggests that RMN could reduce the fluoroscopy time to guide ablation of PVCs.
It was reported that the acute success rate varies between 66%
and 100% and the long-term success rate varies between 60% and 87% for PVC ablation, while in the current study the acute success rate was 90.7% and the long-term success rate was 83.7% with no F I G U R E 3 The overall PVCs free survival curve. Kaplan-Meier estimates overall PVCs free survival rate between EnSite Precision mapping system and CARTO mapping system significant difference between the two groups, which suggests that the collaboration of EnSite Precision with Niobe system was as effective as the collaboration of CARTO3 with Niobe system. 5, 6, [18] [19] [20] 
| Limitations
Although this is currently the first study reporting data from PVC ablation using EnSite Precision combined with RMN, the patient numbers were relatively low hampering more complex analyses, and larger studies are needed. In addition, this study is limited by the inherent nature of a retrospective study and prospective studies are needed to confirm.
| CON CLUS IONS
The current study demonstrates the first clinical experience reporting the utility of EnSite Precision and RMN on ventricular arrhythmia ablation. Our initial data demonstrate that the combination of EnSite Precision and RMN is safe and effective for PVC ablation with both high acute success rates and reasonable long-term outcome. Further large-scale prospective studies with focus on ventricular arrhythmia ablation procedures are warranted to determine a potential benefit for patients' treatment.
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